Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.66 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582656 | 0.92 | MCHR1 (0.69) | MCHR1ITGB3ITGA2BNPC1RAB9A | |
| SCHEMBL5582558 | 0.91 | MCHR1 (0.66) | MCHR1ITGB3ITGA2BNPC1RAB9A | |
| SCHEMBL5583028 | 0.91 | MCHR1 (0.68) | MCHR1ITGB3ITGA2BNPC1RAB9A | |
| SCHEMBL14473031 | 0.83 | MCHR1 (0.77) | MCHR1ITGB3ITGA2BNPC1RAB9A | |
| SCHEMBL5583048 | 0.83 | MCHR1 (0.69) | MCHR1ITGB3ITGA2BNPC1RAB9A | |
| SCHEMBL5582768 | 0.82 | MCHR1 (0.68) | MCHR1ITGB3ITGA2BHTR2C | |
| SCHEMBL5582632 | 0.82 | MCHR1 (0.69) | MCHR1ITGB3ITGA2B | |
| SCHEMBL5582713 | 0.81 | MCHR1 (0.68) | MCHR1ITGB3ITGA2B | |
| SCHEMBL5582629 | 0.81 | MCHR1 (0.52) | MCHR1ITGB3ITGA2B | |
| SCHEMBL2669493 | 0.80 | MCHR1 (1.00) | MCHR1ITGB3ITGA2BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885ITGB3 4150/4885ITGA2B 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.